V
enous thromboembolism (VTE) is traditionally associated with red blood cell and fibrin-rich red clot formed under low flow-rate conditions, whereas arterial thrombi, formed at higher flow rates, are rich in platelets, often giving the appearance of white clot. This simple but dogmatic concept has had important therapeutic implications over the past decades, with anticoagulant therapy considered the treatment of choice for the management and prevention of venous thrombosis, whereas antiplatelet therapy is the cornerstone for the treatment and prevention of arterial thrombosis.
Observational studies have suggested an association between symptomatic atherosclerosis and VTE risk. [1] [2] [3] In addition, studies testing statin therapy to reduce atherothrombotic events in patients at risk for atherosclerosis have also demonstrated reductions in VTE possibly through anti-inflammatory mechanisms. 4 Although anticoagulation is the most effective treatment for VTE, several studies have demonstrated that aspirin monotherapy is effective for primary and secondary prevention of VTE. [5] [6] [7] [8] [9] [10] In the setting of primary prevention, a meta-analysis by the Antiplatelet Trialists' Collaboration observed a reduction in the incidence of deep vein thrombosis (DVT) by 20% and of pulmonary embolism (PE) by 69% in surgical and high-risk medical patients receiving aspirin monotherapy. 5 Moreover, randomized trials have demonstrated a 32% reduction in recurrent VTE with aspirin versus placebo in patients with a history of VTE. 9, 10 Whether these benefits are driven primarily by the antiplatelet effects of aspirin is unknown.
We hypothesized that, in 2 large trials designed to test the efficacy of more intensive antiplatelet therapy for the reduction of long-term ischemic risk in stable outpatients with symptomatic atherosclerosis, VTE would be significantly associated with more severe symptomatic arterial vascular disease. In addition, we hypothesized that the addition of other antiplatelet agents to standard background therapy, including aspirin, would further reduce VTE risk. To test these hypotheses, we ascertained and characterized symptomatic VTE events in 47 611 patients randomized in the TRA2P-TIMI 50 trial (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction) and the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). 11, 12 We evaluated risk of symptomatic VTE over time, independent risk factors for VTE, and efficacy of more intensive antiplatelet strategies at reducing VTE risk.
METHODS

Study Design and Population
The TRA2P-TIMI 50 trial randomized 26 449 stable outpatients with a history of myocardial infarction (MI), ischemic stroke, or peripheral artery disease (PAD). The study design and main results have been reported previously. 11, 13 In brief, the study population was randomized to receive vorapaxar, an oral competitive antagonist of PAR-1, 2.08 mg daily, or a matching placebo. Background antithrombotic therapy was at the discretion of the treating physicians and included aspirin monotherapy (N=11 093) or clopidogrel (N=15 356). Patients were excluded if they had a history of bleeding diathesis, experienced recent active abnormal bleeding, or were receiving ongoing treatment with anticoagulants. Patients were stratified at randomization hierarchically by symptomatic disease state, and a detailed vascular history was collected at baseline in all patients. 11, 13 The primary efficacy end point was a composite of cardiovascular death, MI, stroke, or recurrent ischemia leading to urgent coronary revascularization. Median follow-up was 30 months.
The PEGASUS-TIMI 54 trial randomized 21 162 stable patients with a history of MI 1 to 3 years before enrollment. The design and main results of this trial have been reported previously. 12, 14 In brief, the study population was randomized to treatment with ticagrelor (90 or 60 mg twice daily) or placebo in addition to low-dose aspirin. Patients were ineligible if there was planned use of anticoagulant therapy during the study period. A vascular history, including the presence of symptomatic PAD and cerebrovascular disease, was collected at baseline. 12, 14, 15 The primary efficacy end point was the composite of cardiovascular death, MI, or stroke. Median followup was 33 months. The present analysis was prespecified in the protocol.
For both trials, the protocol was approved by the relevant ethics committee at each participating site, and written informed consent was obtained from all the patients.
Clinical Perspective
What Is New?
• This aggregate report from 2 large randomized trials demonstrates for the first time that more potent antiplatelet therapy further lowers venous thromboembolism (VTE) risk relative to aspirin alone.
• Other mechanisms of platelet inhibition (P2Y 12 inhibition and PAR-1 antagonism) appear to lower VTE risk.
• The degree of atherosclerotic burden as characterized by polyvascular disease is associated with increased VTE risk.
What Are the Clinical Implications?
• More intensive antiplatelet strategies for secondary prevention of atherosclerotic events may also reduce VTE risk in this population.
• Future trials evaluating therapeutic strategies for secondary prevention in patients with vascular disease should evaluate VTE as a potentially modifiable end point.
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Identification of Venous Thrombotic Events
Two blinded vascular specialists (I.C., M.P.B.) independently reviewed listings of preferred terms, lower level terms, verbatim terms, and narratives from the safety datasets of the TRA2P-TIMI 50 and PEGASUS-TIMI 54 trials using systematic criteria to identify potential symptomatic PE and DVT events. Potential events were reviewed in detail, including narratives describing symptoms, diagnostic testing, and treatment. Primary terms used to define VTE events included DVT, PE, and vein thrombosis. Based on review of all available data, the 2 reviewers independently determined whether a symptomatic VTE event occurred and was categorized as DVT or PE. If the 2 reviewers agreed, then an event was determined to have occurred, whereas disagreements were resolved by discussion and consensus. The primary outcome of this analysis was the incidence of symptomatic VTE defined as a composite of PE and DVT. Both studies were pooled and then examined individually.
Statistical Analysis
The primary efficacy analysis was conducted on an intentionto-treat basis among all patients who underwent randomization. The treatment effect was formally assessed by Cox regression using all available follow-up. Kaplan-Meier event rates were calculated at 3 years by randomized treatment.
A time-to-event analysis was conducted for the first symptomatic VTE event. For evaluating recurrent VTE events, negative binomial regression analysis was performed to compare intervention and placebo arms using pooled trial data. Negative binomial regression analysis results are reported by incidence-rate ratio with 95% confidence intervals (CIs). Baseline characteristics of patients were compared based on the incidence of VTE during follow-up using χ 2 test for categorical variables and Wilcoxon rank-sum test for continuous variables. Continuous variables are presented as median and interquartile ranges, and categorical variables are presented as numbers and percentages. Cox proportional hazards regression analysis was used to identify variables independently associated with the incidence of VTE in the studies' placebo arm. Consistent with prior analyses of polyvascular disease, patients were categorized by number of symptomatic vascular territories (coronary, peripheral, and cerebrovascular) as having 1-, 2-, or 3-vessel disease. 16 Polyvascular disease was defined as a preexisting disease in multiple territories (≥2 vascular territories with preexisting atherosclerotic involvement). 16 The crude associations between VTE and different baseline variables were first quantified by univariate Cox regression. All covariates that reached a significance level of P<0.10 were then included in a multivariate Cox regression model, where backward selection was applied to obtain a final model (P for retention in the model <0.05). To combine data from both trials, we performed a standard meta-regression analysis through a fixed-effects model using the MantelHaenszel method to estimate pooled hazard ratios (HRs). The extent of inconsistency between results was determined with I-squared statistics. Results are presented as HRs with 95% CIs. Statistical analysis was performed using SAS version 9.4 (SAS Institute Inc) and Stata version 14 (StataCorp LP). The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
RESULTS
A total of 47 611 patients were randomized in the 2 trials and were followed for a median of 31.4 months. Over this time, 343 symptomatic VTE events occurred in 301 patients, including 166 PE events and 177 DVT events. At 3 years, the rate of VTE in patients randomized to placebo was 0.95% in TRA2P-TIMI 50 and 0.87% in PEGASUS-TIMI 54 ( Figure 1) , with a composite placebo rate of 0.93% in both trials combined. In TRA2P-TIMI 50, the 3-year rates of VTE by qualifying disease state were 0.63% for patients with a history of MI, 1.36% for those with established PAD, and 0.82% for the group with prior stroke. Baseline features of patients who experienced VTE are summarized in Table 1 . In brief, patients who had VTE were more likely to be older, have a higher body mass index, hypertension, diabetes mellitus, impaired renal function, chronic obstructive pulmonary disease, atrial fibrillation or flutter, heart failure, prior coronary bypass artery grafting, PAD, history of stroke or transient ischemic attack, and polyvascular disease. 
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Clinical Predictors of VTE
Univariate and independent predictors of VTE were evaluated in the placebo arm of each trial separately (TRA2P-TIMI 50, Tables I and II in the online-only Data  Supplement; PEGASUS-TIMI 54, Tables III and IV in the online-only Data Supplement) and in the placebo arm of both trials pooled (Table 2 and Table V in the onlineonly Data Supplement). In each trial, age and higher body mass index were significantly associated with VTE risk. When pooling both trials, the risk of VTE was significantly associated with age, higher body mass index, history of chronic obstructive pulmonary disease, and history of atrial fibrillation or flutter and polyvascular disease (C-statistic, 0.684). Prior history of malignancy was collected in PEGASUS-TIMI 54 only, and after adjustment a trend remained toward heightened risk of VTE (HR adj , 2.22; 95% CI, 0.99-4.94; P=0.052). Other factors, including history of heart failure, diabetes mellitus, renal dysfunction (estimated glomerular filtration rate <60 mL/min), and hypertension, were associated with VTE on univariate analysis. However, after adjustment for other covariates, these factors were no longer significantly associated with VTE risk.
Polyvascular Atherosclerosis and VTE
The burden of symptomatic atherosclerosis manifested as an increasing number of symptomatic vascular territories, was associated with a graded increase in the rate of VTE, with 3-year rates by number of symptomatic vascular territories of 0.76% for 1, 1.53% for 2, and 2.45% for 3 symptomatic territories (Figure 2) . After adjustment for baseline differences, there remained a significant graded increase in the risk of VTE, with increasing number of symptomatic territories, including a 62% increase in risk with 2 territories versus 1 (HR adj , 1.62; 95% CI, 1.09-2.40; P=0.016) and a >2-fold risk in those with 3 territories versus 1 (HR adj , 2.04; 95% CI, 1.10-3.77; P=0.024) (Figure 2 ).
Setting of VTE and Outcomes After VTE
The majority of VTE events (47%) occurred as outpatients and led to subsequent hospitalization with a primary diagnosis of VTE, whereas 24% occurred in patients hospitalized for other reasons, and 29% occurred and were treated as outpatients ( Figure I in the online-only Data Supplement). Patients who were hospitalized primarily for VTE had a 9% in-hospital mortality risk. Of those who survived to discharge, mortality rates at 30 and 120 days were 3% and 8%, respectively. The most frequent non-VTE diagnoses leading to hospitalization in which a VTE subsequently occurred were bleeding/malignancy (32%), infection or pulmonary disease (23%), cardiovascular event (16%), elective procedure/musculoskeletal disorder (16%), or other medical illness (13%).
Overall, outcomes 6 months after a VTE event included 5% having recurrent VTE, 7% having a major adverse cardiovascular event, and 13% with 6-month mortality ( Figure 3 ). The majority of the causes of death after VTE were noncardiovascular (59%) compared with cardiovascular (38%) and those in which the cause was unknown (3%). In PEGASUS-TIMI 54, adjudicated causes of death included noncardiovascular subtypes such as malignancy. In this dataset, 86% of noncardiovascular deaths after VTE were because of malignancy.
Intensive Antiplatelet Therapy and VTE
When combining data from both trials, the 3-year incidence of VTE was 0.64% in the more intensive antiplatelet arm and 0.93% in the placebo arm, reflecting a 29% relative risk reduction with more intensive antiplatelet therapy (HR, 0.71; 95% CI, 0.56-0.89; P=0.003; I-squared 0) (Figures 4 and 5) . No significant 
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Antiplatelet Therapy for Venous Thromboembolism heterogeneity was discovered between the trials. Total VTE events were significantly reduced by 31% with more intensive antiplatelet therapy as compared with placebo (incidence-rate ratio, 0.69; 95% CI, 0.54-0.88:
P=0.003).
In TRA2P-TIMI 50, the addition of vorapaxar 2.08 mg daily to aspirin with or without clopidogrel was associated with a 35% reduction in the incidence of VTE compared with placebo (3-year KM event rate 0.66% versus 0.95%; HR, 0.65;, 95% CI, 0.48-0.88; P=0.006) ( Figure II in the online-only Data Supplement). In a subgroup analysis, among patients on background aspirin alone, the 3-year event rates were 1.11% with placebo and 0.51% with vorapaxar, resulting in a 58% relative risk reduction (HR, 0.42; 95% CI, 0.25-0.71) with dual antiplatelet therapy versus monotherapy. Among patients on background aspirin and clopidogrel, the 3-year event rates were 0.84% with placebo and 0.78% with vorapaxar, resulting in an HR of 0.84 (95% CI, 0.57-1.23) with triple versus dual antiplatelet therapy (P-interaction 0.037) ( Figure III in the onlineonly Data Supplement).
In PEGASUS-TIMI 54, the addition of ticagrelor to low-dose aspirin was associated with a 21% numeric trend in reduction of VTE over a median follow-up of 33 months compared with placebo (HR for ticagrelor pooled doses, 0.79; 95% CI, 0.55-1.13; P=0.19) (Figure IV 
DISCUSSION
This analysis shows that patients with symptomatic atherosclerosis without an indication for anticoagulation have an accumulated risk of VTE at a rate of ≈0.3% per year while on treatment with ≥1 antiplatelet agent. This incidence rate of VTE appears comparable to those in other stable VTE primary prevention cohorts. 4, 17 Three novel findings are presented in this study. First, although prior trials have shown the efficacy of aspirin monotherapy for VTE prevention, this 
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Cavallari et al Antiplatelet Therapy for Venous Thromboembolism aggregate report from 2 large randomized trials demonstrates that more potent antiplatelet therapy further lowers VTE risk relative to aspirin and/or clopidogrel. Second, other mechanisms of platelet inhibition (P2Y 12 inhibition and PAR-1 antagonism) appear to lower VTE risk. Third, the degree of atherosclerotic burden as characterized by polyvascular disease is associated with increased VTE risk. VTE is one of the most frequent cardiovascular events, with an overall annual incidence of 100 to 200 per 100 000 persons. 18, 19 Although risk factors for VTE have traditionally been described as immobilization (eg, recent surgery, travel, hospitalization), trauma, and malignancy, increasing evidence indicates that atherosclerotic vascular disease may also be associated with increased risk of VTE.
1-3 A large population-based cohort study reported a significantly increased relative risk of MI in the first year after VTE, varying from 1.6 after DVT to 2.6 after PE. 2 The relative risks were also raised, although less markedly, during the subsequent 20 years of follow-up, with 20% to 40% increases in risk for arterial cardiovascular events.
2 Because VTE and atherosclerosis share common risk factors such as age, it has been unclear whether the association between symptomatic atherosclerosis and VTE is because of shared risk factors or shared pathobiology. It is plausible that inflammation plays a key role in this association, increasing both blood coagulability and platelet turnover. In the current study, the finding of the significant and graded association between polyvascular disease and increasing VTE risk further supports this hypothesis and adds to the body of evidence demonstrating the relationship between polyvascular disease and thrombotic complications. 20, 21 Antiplatelet therapy has been shown in various settings to reduce the risk of MI, ischemic stroke, and other manifestations of arterial occlusion, 22 and it is widely prescribed, with ≈70% of American adults with atherosclerotic cardiovascular disease chronically treated with aspirin. 23 Over the past 2 decades, antiplatelet agents were rarely considered for the prevention of VTE because of the lack of convincing evidence. Yet the efficacy of an antiplatelet agent for preventing VTE is biologically plausible because of the involvement of platelets in the formation of venous thrombi and the evidence of increased levels of markers of platelet and endothelial activation in patients with VTE. [24] [25] [26] [27] In fact, the Antiplatelet Trialists' Collaboration meta-analysis showed that a few weeks of antiplatelet therapy roughly halved the risk of both DVT and PE in a wide range of patients. 5 The combined results of the WARFASA (Warfarin and Aspirin) and ASPIRE (Aspirin to Prevent Recurrent Venous Thromboembolis), randomized trials of aspirin versus placebo for secondary prevention in patients with prior VTE, demonstrated a highly significant 32% reduction in the rate of recurrent VTE and a 34% reduction in the rate of major vascular events, with no excess of bleeding in patients randomized to aspirin versus placebo administered after 6 to 24 months of oral anticoagulation. 9, 10 This 32% risk reduction corresponds to <50% of the degree of risk reduction achieved by oral anticoagulants but with the benefit of lower bleeding rates (≈1.35% per patient-year during treatment with aspirin). 17 The current study demonstrates, for the first time, that more intensive antiplatelet therapy when added to aspirin alone or aspirin plus clopidogrel is associated with a further 29% risk reduction in VTE. This finding was consistent with 2 antiplatelet agents with different mechanisms of action, including vorapaxar (a PAR-1 antagonist) and ticagrelor (a P2Y 12 inhibitor). This observation further underscores the role of the platelet in the pathogenesis of VTE and the cross-talk between platelet activation and the coagulation cascade. Indeed, much debate regarding the white clot/red clot paradigm is expected in the near future. The COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Stratgies) has recently shown that, in patients with coronary artery disease or PAD, low-dose anticoagulation with rivaroxaban 2.5 mg twice daily added to low-dose aspirin resulted in a 24% relative risk reduction in the incidence of cardiovascular death, MI, and stroke compared with aspirin alone. 28 In addition, a trend occurred for reduction in VTE (HR, 0.61; 95% CI, 0.37-1.00; P=0.05). The findings of this analysis do not support the use of a more intensive antiplatelet regimen in lieu of anticoagulant therapy. However, in patients at risk for VTE who are not prescribed anticoagulation, these data may suggest an additional consideration for the clinician considering intensifying antiplatelet therapy or discontinuing dual-antiplatelet therapy in favor of a single antiplatelet strategy.
This study has several limitations. First, VTE was not a prespecified outcome in TRA2P-TIMI 50; thus, screening for VTE was not performed and analyses should be considered exploratory. Adjudication of VTE is challenging; multiple criteria for the classification of events based on the availability of confirmatory tests have been proposed over time. 29, 30 Although symptomatic events were ascertained retrospectively, they were done so by using a formal adjudication process and by 2 blinded vascular specialists. The retrospective nature of event collection may lead to underascertainment of events. Thus, the observed event rate may underestimate the true event rate. However, it is reassuring that the frequency of VTE among the participants of TRA2P-TIMI 50 and PEGASUS-TIMI 54 to 301 cases overall (≈0.3% per year in the placebo arm) is comparable to or even exceeds the ones reported in other VTE primary prevention cohorts, especially given the risk reduction conferred by aspirin. 4, 17 Evaluation of randomized treatment, however, should not be af-
Cavallari et al Antiplatelet Therapy for Venous Thromboembolism fected, and lack of specificity would be expected to bias results toward the null. In evaluating the relationship between polyvascular disease and risk of VTE, we adjusted for all known baseline imbalances; however, it is possible that residual confounding remains. Descriptive data presented describing high rates of adverse outcomes after VTE likely reflect in part the overall illness of patients who develop VTE and should not be interpreted as necessarily causally related to the VTE event.
The results of this study should not be interpreted as advocating the use of intensive antiplatelet therapy for VTE prevention in patients with symptomatic atherosclerosis. Rather, these results are meant as an exploratory analysis evaluating potential efficacy, and the hypothesis generated by these findings along with bleeding risk of additional antiplatelet therapy would have to be evaluated in prospective randomized trials.
In conclusion, patients with symptomatic atherosclerosis are at risk for VTE, and that risk increases with the burden of disease as manifested by the number of symptomatic vascular territories. In patients experiencing VTE, rates of subsequent cardiovascular complications are high, and death is predominantly because of noncardiovascular causes including malignancy. More intensive antiplatelet strategies for secondary prevention of atherosclerotic events may also reduce VTE risk in this population. Future trials evaluating therapeutic strategies for secondary prevention in patients with vascular disease should evaluate VTE as a potentially modifiable end point.
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